Literature DB >> 7359966

Upper esophageal sphincter: pre and post-laryngectomy--a normative study.

G A Gates.   

Abstract

Correlation of anatomical, surgical, manometric, and radiographic observations leads to the conclusion that the normal high pressure zone of the pharyngoesophageal junction is composed of two parts: an annular muscular sphincter in the most proximal part of the upper esophagus and, above this, a complex pinchcock sphincter composed of the cricoid cartilage anteriorly and cricopharyngeus muscle laterally and posteriorly. The pinchcock part of the sphincter produces a high pressure zone in a predominantly anteroposterior direction. After laryngectomy, the sphincter becomes completely annular and behaves like a pure musculare constrictor; it is likely that both the cricopharyngeus and the upper esophageal circular muscles constitute the postlaryngectomy pharyngoesophageal high pressure zone. The relative contributions of the pinchcock segment (upper part) and annular constrictor segment (lower part) to the overall function of the upper esophageal sphincter have yet to be established in man.

Entities:  

Mesh:

Year:  1980        PMID: 7359966     DOI: 10.1002/lary.5540900312

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  3 in total

1.  Submucosal Elastic Laminae of the Middle and Lower Pharynx: A Histological Study Using Elderly Cadaveric Specimens.

Authors:  Ai Kawamoto-Hirano; Yohei Honkura; Masahito Yamamoto; Shin-Ichi Abe; Gen Murakami; Yukio Katori
Journal:  Dysphagia       Date:  2016-07-19       Impact factor: 3.438

2.  Multivariable analysis of risk factors for enlargement of the tracheoesophageal puncture after total laryngectomy.

Authors:  Katherine A Hutcheson; Jan S Lewin; Erich M Sturgis; Jan Risser
Journal:  Head Neck       Date:  2011-06-20       Impact factor: 3.147

3.  Rehabilitation of dysphagia following head and neck cancer.

Authors:  Barbara R Pauloski
Journal:  Phys Med Rehabil Clin N Am       Date:  2008-11       Impact factor: 1.784

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.